TABLE 2.
Characteristics of patients comparing dose intensities
| Patient Characteristic |
<50% n (%) N = 304 |
50%‐75% n (%) N = 163 |
>75% n (%) N = 214 |
P |
|---|---|---|---|---|
| Age, years | 65 | 66 | 61 | <.001 |
| Mean | 255 (84%) | 34 (21%) | 169 (79%) | |
| ≥70 | 49 (16%) | 129 (79%) | 45(21%) | |
| Gender | .718 | |||
| Male | 240 (79%) | 133 (82%) | 174 (81%) | |
| Female | 64 (11%) | 30 (18%) | 40 (19%) | |
| Ethnicity | .185 | |||
| East‐Asian | 123 (40%) | 56 (34%) | 71 (33%) | |
| Other | 181 (53%) | 107 (66%) | 143 (67%) | |
| Liver disease etiology | .189 | |||
| None | 59 (19%) | 24 (15%) | 34 (16%) | |
| Hepatitis B | 103 (34%) | 50 (31%) | 69 (32%) | |
| Hepatitis C | 93 (31%) | 46 (28%) | 56 (26%) | |
| Alcohol | 27 (9%) | 29 (18%) | 36 (17%) | |
| NASH | 11 (4%) | 7 (4%) | 14 (6%) | |
| Other | 11 (4%) | 7 (4%) | 5 (2%) | |
| Any prior treatment | 88 (29%) | 47 (29%) | 76 (35%) | .224 |
| Liver Resection | 76 (25%) | 37 (23%) | 50 (23%) | .833 |
| Radiofrequency Ablation | 78 (26%) | 33 (20%) | 37 (17%) | .066 |
| Alcohol Injection | 12 (4%) | 5 (3%) | 7 (3%) | .861 |
| Bland Embolization | 11 (4%) | 4 (2%) | 6 (3%) | .755 |
| TACE | 115 (38%) | 57 (35%) | 55 (26%) | .14 |
| TARE | 6 (2%) | 6 (4%) | 10 (5%) | .216 |
| Baseline AFP level | .647 | |||
| >400 | 135 (44%) | 64 (39%) | 89 (42%) | |
| ≤400 | 150 (49%) | 85 (52%) | 111 (52%) | |
| Unknown | 19 (6%) | 14 (9%) | 14 (6%) | |
| Baseline ECOG performance status | .015 | |||
| 0‐1 | 257 (84%) | 147 (90%) | 191 (89%) | |
| 2 | 40 (13%) | 16 (10%) | 18 (8%) | |
| 3‐4 | 4 (1%) | 0 | 4 (2%) | |
| Baseline liver function (Child‐Pugh) | .648 | |||
| A | 254 (83%) | 143 (88%) | 188 (88%) | |
| B | 47 (15%) | 20 (12%) | 25 (12%) | |
| C | 1 (<1%) | 0 | 0 | |
| Baseline metastatic disease | .207 | |||
| Yes | 138 (45%) | 71 (43%) | 111 (52%) |
Abbreviations: AFP, alpha fetoprotein; ECOG, Eastern Cooperative Oncology Group; NASH, non‐alcoholic steatohepatitis; TACE, trans‐arterial chemoembolization; TARE, trans‐arterial radioembolization.